Dr. Jeff Leiden Receives the 2018 Service to Science Industry Leadership Award for Vertex’s Advances in CF Research

 

February 1, 2018


From left: Bill Leinweber, NDRI President & CEO, Dr. Jeff Leiden, and Dr. Arthur Rubenstein, NDRI Board Member

During an evening of recognizing leaders and pioneers across the biomedical innovation ecosystem, the National Disease Research Interchange (NDRI) honored our CEO Dr. Jeff Leiden as the recipient of the Service to Science Pharmaceutical Industry Leadership Award. Vertex was recognized for our significant advances in cystic fibrosis (CF) research, alongside the CF community, that have resulted in the first medicines to treat the underlying cause of the disease.

Our journey in CF spans nearly two decades, billions of dollars and hundreds of researchers in the relentless pursuit of medicines that strike at the core of cystic fibrosis. The progress we’ve made – bringing two transformative medicines to patients in six years – is only possible through our partnerships with thousands of physicians, patients, advocates, regulators and so many others across the innovation ecosystem who share our goal of bringing a medicine to all people living with this life-shortening disease. Our work is far from done and we are continuing to push the boundaries of science for those who are still waiting. 

About Vertex  About Jeff